Australian veterinary drug developer Nexvet racks up $31.5 mln

Nexvet Biopharma has closed $31.5 million in Series B financing. Investors included Farallon Capital Management, Adage Capital Partners, Foresite Capital and Tavistock Life Sciences subsidiary fund Boxer Capital. Based in Melbourne, Australia, Nexvet is a veterinary biologic drug developer.

PEHUB Community

Join the 12503 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget